NCT02824029 2025-02-17Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaBarbara Ann Karmanos Cancer InstitutePhase 2 Completed28 enrolled 11 charts
NCT02869633 2023-10-23Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell TransplantVanderbilt-Ingram Cancer CenterPhase 2 Completed23 enrolled 10 charts